Skip to content
lifestyle.theroguemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kymera Therapeutics, Inc.
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
September 2, 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
September 1, 2026
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
August 5, 2026
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
July 28, 2026
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
July 27, 2026
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
June 9, 2026
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
June 8, 2026
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
June 8, 2026
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 27, 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
May 24, 2026
1
2
Next Page
→